	US 11,905,258 B2
	2-aminoaryl-5-aryloxazole analogs for the treatment of neurodegenerative diseases
Mark J. Suto, Homewood, AL (US); Bini Mathew, Hoover, AL (US); Rita Cowell, Hoover, AL (US); and Corinne E. Augelli-Szafran, Homewood, AL (US)
Assigned to Southern Research Institute, Birmingham, AL (US)
Filed by Southern Research Institute, Birmingham, AL (US)
Filed on Aug. 22, 2022, as Appl. No. 17/893,091.
Application 17/893,091 is a continuation of application No. 16/968,039, granted, now 11,472,781, previously published as PCT/US2019/018834, filed on Feb. 20, 2019.
Claims priority of provisional application 62/633,577, filed on Feb. 21, 2018.
Prior Publication US 2023/0002331 A1, Jan. 5, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 263/48 (2006.01); C07D 413/04 (2006.01)

CPC C07D 263/48 (2013.01) [C07D 413/04 (2013.01)]

13 Claims

1. A compound having a structure represented by a formula:

wherein R¹is selected from hydrogen and C1-C4 alkyl;

wherein Ar¹is selected from monocyclic aryl and pyridinyl, and is substituted with 0, 1, 2, or 3 groups independently selected from halogen, —CN, —NH₂, —OH, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino;

wherein Ar³is pyridinyl substituted with 0, 1, 2, or 3 R⁴groups; and

wherein each occurrence of R⁴is independently selected from halogen, —CN, —NH₂, —OH, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 hydroxyalkyl, C1-C4 alkoxy, C1-C4 alkylamino, and (C1-C4)(C1-C4) dialkylamino,

or a pharmaceutically acceptable salt thereof.